Maggie L. Shaw

Data from the GLOW study of minimal residual disease evaluation following chemotherapy for chronic lymphocytic leukemia (CLL) show the kinase inhibitor/B-cell lymphoma-2 inhibitor pair produced superior outcomes compared with the alkylating agent/monoclonal antibody combination.

Adriaan Voors, MD, professor of cardiology and director of the Heart Failure Clinic, University Medical Center Groningen, the Netherlands, explains why patients provided sodium-glucose co-transporter 2 (SGLT2) inhibitors in hospitals may be unable to continue the medication after discharge.

This year’s most-read articles on endocrinology posted at AJMC.com were concentrated in 3 areas: hormone therapy, treatment for growth hormone deficiency among pediatric patients, and outcomes among women with polycystic ovary syndrome.

This year’s most-read articles on pulmonary arterial hypertension (PAH) covered a range of topics, including nutrition, therapy switches, and patient education to improve treatment adherence. Improving patient outcomes is something they all had in common.

In an interview conducted before the highly transmissible Omicron coronavirus variant began driving another wave of infections, Peter Hotez, MD, PhD, FASTMH, discussed the struggle public health officials and scientists have in fighting false beliefs about vaccinations.

HIV specialist dieticians at this London-based charity help people with HIV by providing personalized advice on how nutrition can have a positive effect on their overall health and well-being.

Jason Myers, PhD, CEO, of the New Zealand AIDS Foundation, explains how they conducted a New Zealand version of the Stigma Index Research to solve the issue of Māori living with HIV experiencing worsened stigma and discrimination.

Debra Patt, MD, PhD, MBA, of Texas Oncology, and Lucio Gordan, MD, of Florida Cancer Specialists, MD, presented data from a study they conducted in partnership with the Community Oncology Alliance and Avalere Health.

The discussion, "Remote Patient Monitoring: Case Studies From the Front Lines,” explored real-world experiences with technology that has taken on greater heft as the COVID-19 pandemic continues to affect health care delivery.

Adriaan Voors, MD, University Medical Center Groningen, the Netherlands, discusses how and why sodium-glucose co-transporter 2 (SGLT2) inhibitors act so quickly for patients with heart failure.

Among the issues presented in patients with Turner syndrome, short stature is one of the most prominent, and investigators from Korea investigated the effects of a new recombinant growth hormone among this population.

Final results from the MASTER trial presented at this year’s 63rd Annual American Society of Hematology Annual Meeting and Exposition bear out the benefits of quadruplet therapy and using minimal residual disease (MRD) status among patients with newly diagnosed multiple myeloma (MM).

An abstract presented at the 63rd Annual American Society of Hematology Annual Meeting and Exposition shows that although daratumumab use in multiple myeloma holds great promise, challenges remain in the use of clinical pathways for treatment direction with the monoclonal antibody—which the investigators say may also present opportunities for change.

This new review examined oral health outcomes in children with growth hormone deficiency (GHD) following a search of the published literature from January 2000 through May 2021.

The CDC’s latest Morbidity and Mortality Weekly Report details the care and HIV service disparities that persist among sexual minority men.

Findings presented today during EuroEcho 2021 demonstrate a potential link between persistent dyspnea following recovery from COVID-19 infection and subclinical cardiac dysfunction.

A secondary analysis of economic outcomes–related data from the Rehabilitation Therapy in Older Acute Heart Failure Patients trial attempted to answer if a novel 12-week rehabilitation intervention held cost-effective value.

This new study investigated a potential link between genetically predicted polycystic ovary syndrome (PCOS) and greater risk of endometrial cancer among patients of European and Asian ancestries.

Multidisciplinary care that includes growth hormone treatment should not cease once patients with Prader-Willi syndrome reach adulthood, according to authors of a study on care outcomes.

Adriaan Voors, MD, discusses possible mechanisms of action of empagliflozin that produce such beneficial results among patients with heart failure, in an interview about the EMPULSE trial prior to this year’s American Heart Association Scientific Sessions.

This new study from Finland highlights both the potential for severe psychiatric disturbances among women with polycystic ovary syndrome (PCOS) and lack of extensive knowledge of the toll of psychoses among this group.

This new investigation into the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors for heart failure shows significant benefit in persons with heart failure with preserved ejection fraction (HFpEF).

This new review from China investigated the relationship between diet and fertility among women with polycystic ovary syndrome (PCOS) and provides clinical and evidence-based nutrition recommendations to help manage their reproductive health.

This study from Japan investigated the impact of early initiation of growth hormone (GH) treatment on puberty onset and adult height outcome.

Will Nutland, DrPH, is cofounder of PrEPster, an honorary assistant professor at the London School of Hygiene and Tropical Medicine, and an activist.

A new analysis of data from the HOMAGE study addresses previous mixed results on the use of aspirin among patients who may be at risk of heart failure (HF).

Adherence to antiretroviral treatment (ART) for HIV among Black sexual minority men who have sex with men remains below that of their White counterparts, as does the resulting viral suppression.

Wanting more data on the benefits of sacubitril/valsartan vs renin angiotensin system inhibitor background therapy, investigators conducted a large randomized study among persons with heart failure with preserved ejection fraction (HFpEF).

Neck circumference may serve as a suitable alternative to waist circumference when gauging cardiometabolic risks, outside of body mass index and waist circumference, among women with polycystic ovary syndrome (PCOS).